Skip to main content
. Author manuscript; available in PMC: 2024 Nov 28.
Published in final edited form as: Cancer Lett. 2023 Nov 2;579:216479. doi: 10.1016/j.canlet.2023.216479

Figure 7. EPHA2 regulates AKT in CLDN1-expressing CRC cells to promote CD44 expression, tumor-initiating potential, and chemoresistance.

Figure 7.

(a) Inhibition of EPHA2 with ALW-II-41-27 reduced AKT activation (p-S473) in both SW480 control and CLDN1 overexpressing cells and significantly decreased CD44 only in SW480cldn1 cells. Cells were incubated overnight in serum-free medium and treated for 4 hours with 1 μM inhibitor followed by 30 minutes incubation with FBS. (b) EPHA2 KO in SW480 CLDN1-expressing cells reduced AKT activation (p-S473) and CD44 expression. (c, d) EPHA2 KO in SW480cldn1 cells reduced both tumor-initiating potential and resistance to 5FU. ELDA data available in Sup. Table 3. (e) EPHA2 expression was positively correlated with chemoresistance in CRC patient datasets (GSE28702 and GSE72970) categorized into responders (n=51) and non-responders (n=37) to FOLFOX. C = Control, KO = Knockout, EPH = EPHA2. * = p<0.05, ** = p<0.01, *** = p<0.001.